Sánchez-Rodríguez MI, Palacios RJM, Ficker LGB, De la Cruz R, Bonfil MA, Vargas RJF, Medellín MB, Galván GE, Jiménez TO, Colorado LJA

Language: Spanish
References: 21
Page: 31-38
PDF size: 213.72 Kb.

ABSTRACT

Coronary stent use has been a cornerstone in the development of coronary intervention. However, restenosis has been the Achilles heel of the procedures, reporting up to 30% in some panels. With the advent of drug eluting stents (DES) was thought that the problem was resolved, however was another problem, thrombosis intrastent, which although not very frequent, when it appears has catastrophic consequences in the patient, from there the need to further investigate devices, to maintain the same or better efficiency, improving, and with a suitable profile. TITAN2 stent (Hexacat) has been shown to reduce restenosis evaluated by angiography and exist ultrasound compared to metallic stent, has also been compared to other studies with stent liberators of drug showing similar results regarding safety and efficacy. Material and methods: Is a descriptive observational retrospective study whose purpose is to know which is the safety and effectiveness in our population not selected, and also compared with another two groups of drug that were put in the same period of time, all data were extracted from the database of the Department of Hemodynamic, was monitoring clinical carried out by Query external and telephone follow-up at 30 days, 6 months and one year. Results: Performed angioplasty at 1,063 patients positioning 1,726 stenting and tried 1,353 arteries (1.62 ± 0.71 stents per patient). At end meet with requirements only 233 patients, stent TITAN2 using 114 and 119 using DES (patients 76 paclitaxel and sirolimus 43 patients), while boarding complex injuries B2-C was greater than the Cypher Gpo vs Taxus-Titan2 (93% 71.1 and 78.1 vs % p = 0.02) the frequency of binary Restenosis (angiographic and clinic) to one year was similar for all groups, 8% vs 6.6% vs 7% (p = 0.5) so also the need to treat the same vessel is also low in three groups (6.1% vs 3.9% vs 7%) nor no statistical difference. The frequency of thrombosis intrastent was 0% for group TITAN2 2.6% in the Taxus group and 0% in Group Cypher, p = 0. 15 is not statistically significant, although it is worth mentioning that for stent TITAN2 single was clopidogrel for 1 to 2 months on average for the DES was 9 months in average. Discussion: in our results stent TITAN2 showed that it is not lower regard to clinical outcomes of a drug-eluting stent even has the advantage that these patients only administer clopidogrel as if outside a metallic stent naked the presence of thrombosis intrastent, our studies show 12 months 0% of thrombosis. While the current follow-up study is 12 months, the TINOX study at five years follow-up to shown naked stents when compared to a lower frequency of cardiovascular events and no thrombosis to 5 años. Conclusion: The study shows that TITAN2 stent has good results to 12 months of follow-up, its results are mostly similar to the of DES even when patients are high risk profile and complex injuries. This record results show then to TITAN2 stent as an option to be considered in patients who have no heart surgery, scheduled, resistance to clopidogrel, acute myocardial infarction, special clinical circumstances shock cardiogenic and even extraclinics situations as attachment to dual therapy for long time.

REFERENCES

1. Abizaid A, Kornowski R, Mintz GS et al. The influence of diabetes mellitus on acute and late outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32: 584-589.

2. Kastrati A, Hall D, Schoring A. Long term outcome after coronary stenting. Curr Control Trials Cardiovasc Med 2000; 1: 48-54.

3. Kastrati A, Mehilli J, DirshingerJ et al. Intracoronary stenting and angiographic results: strut Thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001; 103: 2816-2821.

4. Coated stents for the prevention of restenosis: part II. Circulation 2002; 106: 2859-28866.

5. Jensen LO, Tilsted HH, Thayssen P et al. Paclitaxel and sirolimus stent versus bare metal stents: long term risk of stent Thrombosis and other outcomes. From the Western Denmark Heart Registry. Eurointerv 2010; 5: 898-905.

6. Flores Rios X, Abugattas-de Torre JP, Campo-Perez R et al. Effect of stent thrombosis on the risk-benefit balance of drug eluting stents and bare metal stents. Rev Esp Cardiol 2010; 63: 528-535.

7. Koster R, Vieluf D Kiehn M et al. Nickel and molybdenum contact allergies in patients with coronary in stent restenosis. Lancet 2000; 356: 1895-1897.

8. Windecker S, Mayer I, De Pasquale G et al. Stent coating with titanium .nitride oxide for reduction of neointimal hyperplasia. Circulation 2001; 104: 928-933.

9. Windecker S, Simon R, Lins M et al. Randomized comparison of a titanium-nitride oxide coated stent with stainless steel stent for coronary revascularization. The TINOX trial. Circulation 2005; 111: 1-6.

10. Karjalainen PP, Ylitalo A, Niemela M et al. Two year follow-up after percutaneous coronary intervention with titanium-nitride-oxide-coated stent versus paclitaxel eluting stents in acute myocardial infarction. Ann Med 2009; 41: 599-607.

11. Karjalainen PP, Ylitalo A, Niemela M et al . Titanium-nitride-oxide coated stents versus paclitaxel eluting stents in acute myocardial infarction a 12 months follow up report from TITAX AMI trial. Eurointerv 2008; 4: 234-241.

12. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.

13. Stone GW, Ellis SG, Cox DA et al. A polymer based, paclitaxel eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.

14. Ong AT, Serruys PW, Aoki J et al. The unrestricted use of paclitaxel versus sirolimus eluting stents for coronary artery disease in an unselected population. One year results of the Taxus-stent evaluated at Rotterdam Cardiology Hospital (T SEARCH) registry. J Am Coll Cardiol 2005; 45: 1135-1141.

15. McFadden EP, Stabile E, Regar E et al. Late thrombosis in drug eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004: 1519-1521.

16. Ong AT, McFadden EP, Regar E et al. Late angiographic stent thrombosis (LAST) events with drug eluting stents. J Am Coll Cardiol 2005; 45: 2008-2092.

17. Karjalainen P, Ylitalo A, Juhani KE et al. Real world experience with the TITAN stent: a 9 month follow up report from the Titan PORI Registry. EuroInterv 2006; 2: 187-191.

18. Mosseri M, Tamari I, Plich M et al. Short and long term outcomes of the titanium-NO stent registry. Cardiovasc Revasc Med 2005; 6: 2-6.

19. Mosseri M, Miller H, Tamari I et al. The Titanium –NO stent: results of a multicenter registry. EuroInterv 2006; 2: 192-196.

20. Moschovits A, Simon R, Seidenstucker A et al. Randomized comparison of titanium-nitride-oxide coated stents with bare metal stents: five year follow-up of the TINOX trial. EuroInterv 2010; 6: 63-68.

21. Valdes M, Fernandez J, Bethencourt A et al. The TIBET registry. Clinical and angiographic events in diabetes patients treated with the TITAN stent. Am J Cardiol 2004; 94(Suppl 6A): 47E.